Advertisement MonoSol Rx files false marking lawsuit against BDSI, Meda, Aveva - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

MonoSol Rx files false marking lawsuit against BDSI, Meda, Aveva

MonoSol Rx has filed an amended patent infringement and false marking lawsuit against BioDelivery Sciences International (BDSI), MEDA Pharmaceuticals and Aveva Drug Delivery Systems in the US District Court for the District of New Jersey.

MonoSol Rx’s complained that BDSI, MEDA, and Aveva’s manufacture, marketing, and sale of the Onsolis film products infringe MonoSol Rx’s US patent no 7,824,588 related to methods of making drug-containing films.

MonoSol Rx has filed its patent infringement claim against these defendants initially in November, 2010.

The current amended complaint is additional false marking claims with respect to US patent no 5,800,832.